Abstract

Engineered heart tissues (EHTs) that are fabricated using human induced pluripotent stem cells (hiPSCs) have been considered as potential cardiac tissue substitutes in case of heart failure. In the present study, we have created hiPSC-derived cardiac organoids (hiPSC-COs) comprised of hiPSC-derived cardiomyocytes, human umbilical vein endothelial cells, and human fibroblasts. To produce a beating conduit for patients suffering from congenital heart diseases, we constructed scaffold-free tubular EHTs (T-EHTs) using hiPSC-COs and bio-3D printing with needle arrays. The bio-3D printed T-EHTs were cut open and transplanted around the abdominal aorta as well as the inferior vena cava (IVC) of NOG mice. The transplanted T-EHTs were covered with the omentum, and the abdomen was closed after completion of the procedure. Additionally, to compare the functionality of hiPSC-COs with that of T-EHTs, we transplanted the former around the aorta and IVC as well as injecting them into the subcutaneous tissue on the back of the mice. After 1 m of the transplantation procedures, we observed the beating of the T-EHTs in the mice. In histological analysis, the T-EHTs showed clear striation of the myocardium and vascularization compared to hiPSC-COs transplanted around the aorta or in subcutaneous tissue. Based on these results, bio-3D-printed T-EHTs exhibited a better maturation in vivo as compared to the hiPSC-COs. Therefore, these beating T-EHTs may form conduits for congenital heart disease patients, and T-EHT transplantation can form a treatment option in such cases.

Highlights

  • Heart failure is a fatal condition, and its treatment is limited to heart transplantation

  • Among the four types of cell suspensions, the one composed of 50% human induced pluripotent stem cell (hiPSC)-CMs, 25% human umbilical vein endothelial cell (HUVEC), and 25% normal human dermal fibroblast (NHDF) was seeded within ultra-low attachment 96 U-well plates (SUMITOMO BAKELITE) to form hiPSC-cardiac organoids (COs), such that there were 30,000 cells per well

  • The hiPSC-COs developed in this experiment were formed from purified hiPSC-CMs, HUVECs, and NHDFs seeded in various ratios

Read more

Summary

Introduction

Heart failure is a fatal condition, and its treatment is limited to heart transplantation. In recent times, engineered heart tissues (EHTs) or cardiac organoids (COs) that are fabricated using human induced pluripotent stem cells (hiPSCs) have been considered as potential cardiac tissue substitutes in heart failure patients. These EHTs may be developed in different ways. Tubular Engineered Heart Tissues in vivo the EHTs with a thickness contract are stronger than COs. histological analysis shows that EHTs are mature tissues, but in comparison to adult human heart tissue, they are considered immature. For better neovascularization of the EHTs, endothelial cells can be included in their development process, thereby resulting in better engraftment

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call